Liventa Bioscience Responds To Lawsuit
WEST CONSHOHOCKEN, Pa., April 23, 2014
WEST CONSHOHOCKEN, Pa., April 23, 2014 /PRNewswire/ --Liventa Bioscience,
(formerly AFCell Medical), one of the leading innovators of allograft implants
from human amniotic membrane in the United States, has received notice that
MiMedx Group, Inc. (MDXG), filed a patent infringement lawsuit against it, its
partner in the wound care market, Medline and Liventa's processing partner,
Musculoskeletal Transplant Foundation, Inc. (MTF).
Robin R. Young, CEO of Liventa Bioscience, said, "In our view this suit is
without merit and we are working with counsel to vigorously defend each
specific claim. We believe this suit is an attempt to slow the increasing
inroads of our amniotic tissue wound care coverings among major hospital
networks in the United States. We are also confident that our tissue forms do
not infringe any of the patents asserted by MiMedx."
About Liventa Bioscience
Liventa Bioscience is a privately held, commercial stage biotechnology company
focused on bringing advanced biologics to market. Its innovative allograft
tissue forms come from living donors and are available through independent
distribution. Liventa is currently offering or is in the process of developing
a number of advanced orthopedic biologics. These products include human
collagen membrane sheets derived from placental tissues, flowable wound
coverings, and innovative new soft tissue repair coverings and protective
For more information on Liventa, visit www.liventabioscience.com.
SOURCE Liventa Bioscience
Contact: Joanne Henry, 612-843-2142, email@example.com
Press spacebar to pause and continue. Press esc to stop.